This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Penumbra, Facebook, Softbank, Sony and Honda Motor highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra, Facebook, Softbank, Sony and Honda Motor highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Medical Instruments Stock Outlook: Long-Term Prospects Bright
by Zacks Equity Research
Research and development in the medical instruments industry is on the rise. FDA's approval of gene therapy for inherited renal disease and Big Data for healthcare set to revolutionize the field.
Zacks.com highlights: G-III Apparel Group, HCA Healthcare, US Ecology, Penumbra and North American Construction Group
by Zacks Equity Research
Zacks.com highlights: G-III Apparel Group, HCA Healthcare, US Ecology, Penumbra and North American Construction Group
Brave Market Volatility With These 5 Low-Beta Stocks
by Zacks Equity Research
We create a strategy that shows less risky stocks could also be rewarding if some parameters are considered.
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
DENTSPLY Launches Azento, Improves Digital Implant Workflow
by Zacks Equity Research
DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.
Here's Why You Should Invest in Penumbra (PEN) Stock Now
by Zacks Equity Research
The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.
Allscripts' Sunrise Abstracting Selected by Wyckoff Heights
by Nabaparna Bhattacharya
Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.
Here's Why You Should Hold On to DaVita (DVA) Stock Now
by Zacks Equity Research
Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.
Thermo Fisher to Acquire BD's Advanced Bioprocessing Unit
by Zacks Equity Research
BD's (BDX) Advanced Bioprocessing business generates revenues worth $100 million annually. The unit will be integrated in the Thermo Fisher's (TMO) Life Sciences Solutions Segment.
OPKO Health (OPK) Begins RAYALDEE Phase 2 Clinical Trial
by Zacks Equity Research
OPKO Health's (OPK) consistent focus on enhancing the efficacy of its flagship RAYALDEE platform is likely to lend it a competitive edge in the MedTech space.
Penumbra Launches Reperfusion Catheters, Boosts Neuro Unit
by Zacks Equity Research
Penumbra (PEN) adopts initiatives to boost the highest revenue generating Neuro business.
Neogen's Livestock Genetic Buyout Expands Animal Safety Suite
by Zacks Equity Research
The acquisition of Livestock Genetic will position Neogen (NEOG) as a leading agrigenomics company worldwide.
Here's Why You Should Hold On to Baxter (BAX) Stock Now
by Zacks Equity Research
Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.
Stryker (SYK) to Acquire K2M Group, Fortify Spine Division
by Zacks Equity Research
Post the acquisition, Stryker (SYK) will leverage on K2M Group's (KTWO) complex spine and minimally invasive solutions.
Here's Why You Should Hold On to Stryker (SYK) Stock Now
by Zacks Equity Research
Challenging global economic conditions and supply-side issues are major deterrents to Stryker's (SYK) top line in the near term. The company's significant exposure to robotics is a positive.
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.
Here's Why You Should Invest in Integer (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.
Cerner, Duke Clinical Research Launch Risk Calculator App
by Zacks Equity Research
Cerner (CERN) launches new Risk Calculator app that will check cardiac risk. The company's relentless efforts to digitize its EHR systems is commendable.
Penumbra Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Penumbra has been struggling lately, but the selling pressure may be coming to an end soon.
Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.
Penumbra (PEN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 400.00% and 7.24%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens focus on driving innovation, ramping up production and expanding geographies.
Penumbra (PEN) Q1 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q1.